ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0306

Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Alexis Ogdie1, Taylor Blachley2, Kelechi Emeanuru2, Sven Richter3, Benoit Guerette3 and Philip Mease4, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Corrona, LLC, Waltham, MA, 3Amgen Inc., Thousand Oaks, 4Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

Meeting: ACR Convergence 2020

Keywords: Disease Activity, pain, Patient reported outcomes, Psoriatic arthritis, registry

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Friday, November 6, 2020

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The efficacy of apremilast vs placebo for the treatment of oligoarticular PsA of ≤2 years duration is being investigated in the FOREMOST trial (NCT03747939). There is a paucity of real-world data characterizing patients (pts) with oligoarticular PsA. The Corrona PsA/SpA Registry, a prospective, observational cohort study, collects real-world data on US pts with PsA. The current analysis compared characteristics of pts with early oligoarticular PsA in the Corrona PsA/SpA Registry who would generally meet eligibility criteria for FOREMOST with the remainder of the PsA registry population.

Methods: Pts ≥18 years of age diagnosed with PsA who enrolled in the registry from March 2013 to February 2020 were included in the analysis. The FOREMOST-eligible group consisted of pts diagnosed with PsA within 2 years prior to enrollment who were naive to biologic DMARDs or targeted systemic DMARDs (apremilast or tofacitinib), had a history of ≤1 prior conventional synthetic DMARD (csDMARD [methotrexate, hydroxychloroquine, sulfasalazine, leflunomide]), and had swollen joint counts (0-66) of 2 to 4 and tender joint counts (0-68) of 2 to 4. The remainder of the PsA registry population included pts with PsA who did not meet these criteria. Data on patient demographics, clinical characteristics, treatment, disease activity, and patient-reported outcomes at enrollment are summarized descriptively.

Results: Of the 3,556 pts with PsA enrolled in the registry, 109 (3.1%) were included in the FOREMOST-eligible group and 3,447 (96.9%) comprised the remainder of the PsA registry population. Baseline characteristics among the 2 populations were generally similar, with slightly younger pts and proportionally more women in the FOREMOST-eligible group than in the remainder of the PsA registry population (Table 1). FOREMOST-eligible pts had shorter duration of PsA and shorter time to PsA diagnosis than the remainder of the PsA registry population (Table 1). Prior and current csDMARD use in the FOREMOST-eligible pts was lower than in the remainder of the PsA registry population (Table 1). FOREMOST-eligible pts had higher mean scores for patient-reported pain visual analog scale (VAS) and the Physician’s Global Assessment (PhGA) of PsA VAS, in the context of comparable overall mean DAPSA, cDAPSA, PsA Disease Activity Score (PASDAS), and Routine Assessment of Patient Index Data 3 (RAPID3) scores (Table 2). Compared with the remainder of the PsA registry population, FOREMOST-eligible pts were less likely to be in minimal disease activity and more likely to have moderate disease activity based on the cDAPSA, DAPSA, and PASDAS (Table 2). Prevalence of dactylitis was higher in the FOREMOST-eligible group, whereas prevalence of enthesitis was higher in the remainder of the PsA registry population.

Conclusion: In the Corrona PsA/SpA Registry, pts with early oligoarticular PsA based on approximating FOREMOST trial criteria were the minority of the enrolled pts. Descriptive statistics of this small but understudied population indicated a higher burden of patient-reported pain and PhGA of PsA compared with the remainder of the PsA registry population, suggesting there is unmet need in this population.


Disclosure: A. Ogdie, AbbVie, 5, Amgen, 2, 5, BMS, 1, Celgene, 1, Corrona, 1, Janssen, 1, Eli Lilly, 1, Novartis, 2, 5, Pfizer, 2, 5, National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2, Rheumatology Research Foundation, 2, National Psoriasis Foundation, 2; T. Blachley, Corrona, LLC, 3; K. Emeanuru, Corrona, LLC, 3; S. Richter, Amgen Inc., 1; B. Guerette, Amgen Inc., 1; P. Mease, Amgen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Novartis, 2, 5, 8, Pfizer Inc, 2, 5, 8, Sun, 2, 5, UCB, 2, 5, 8, AbbVie, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, GlaxoSmithKline, 5.

To cite this abstract in AMA style:

Ogdie A, Blachley T, Emeanuru K, Richter S, Guerette B, Mease P. Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/characteristics-of-patients-with-early-oligoarticular-psoriatic-arthritis-in-the-corrona-psoriatic-arthritis-spondyloarthritis-registry/. Accessed March 5, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristics-of-patients-with-early-oligoarticular-psoriatic-arthritis-in-the-corrona-psoriatic-arthritis-spondyloarthritis-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.